• About us
• Contact

Advertisement

Organisation › Details

PharmaMar S.A. (MSE: PHM)

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. *

 

	Start	1986-01-01 established
	Group	PharmaMar (Group)
	Industry	Yondelis®
	Industry 2	lurbinectedin (PM1183)
	Person	Fernandéz Sousa-Faro, José María (Zeltia 201411 Chairman of Zeltia + PharmaMar)
	Person 2	Pieper, Heiner (Zeltia 201507 VP Business Development + Licensing at PharmaMar)
	Region	Madrid
	Country	Spain (España)
	Street	1 Avda. de los Reyes Polígono Industrial La Mina
	City	28770 Colmenar Viejo (Madrid)
	Tel	+34-91-846-60-00
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for PharmaMar (Group)

• [1] PharmaMar S.A.. (2/17/20). "Press Release: PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer". Madrid & Dublin....
• [2] PharmaMar S.A.. (3/25/19). "Press Release: PharmaMar Announces Positive Results in Its Lurbinectedin Monotherapy Trial for Small Cell Lung Cancer". Madrid....
• [3] PharmaMar S.A.. (2/14/18). "Press Release: PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates". Madrid....
• [4] Genomica SAU. (1/18/18). "Press Release: Genomica Opens Its First Subsidiary in China". Madrid....
• [5] PharmaMar S.A.. (1/18/18). "Press Release: Pharma Mar, S.A. Announces the Results of the Phase III Clinical Trial (CORAIL) with Zepsyre (lurbinectedin) in Platinum-resistant Ovarian Cancer patients". Colmenar Viejo (Madrid)....
• [6] PharmaMar S.A.. (5/18/17). "Press Release: PharmaMar Announces New Data with Its Compounds Yondelis and Lurbinectedin during ASCO 2017". Madrid....
• [7] PharmaMar S.A.. (5/17/17). "Press Release: PharmaMar and Specialised Therapeutics Asia Sign Licensing and Marketing Agreement for Lurbinectedin Covering Australia, New Zealand and Several Asian Countries". Madrid....
• [8] PharmaMar S.A.. (5/4/17). "Press Release: Aplidin Receives Orphan Drug Status for the Treatment of Multiple Myeloma in Switzerland". Madrid....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.